Minerva Neurosciences Announces Financing of up to $200 Million, Led by Vivo Capital, to Advance Its Schizophrenia Drug Roluperidone.
Amount Raised
$200 Million
Round Type
Funding Round
BurlingtonBiotechnologyFood and BeverageAgriculture and FarmingHealth CareTherapeuticsPharmaceuticalBiopharmapharmaceuticalsInvestors
Description
Minerva Neurosciences announced a private placement agreement with institutional investors to raise up to $200 million. An initial $80 million is provided upfront via a new Series A preferred stock issuance, with an additional $120 million contingent on future milestones. The financing is led by Vivo Capital alongside other notable healthcare-focused funds. Proceeds will support a Phase 3 trial of roluperidone and the resubmission of its NDA to the FDA.
Quick answer
Minerva Neurosciences raised $200 Million in a Funding Round round, dated October 21, 2025. Investors: Janus Henderson, Farallon and Vivo Capital. Minerva Neurosciences is based in Burlington, Massachusetts, United States.
- How much did Minerva Neurosciences raise?
- Minerva Neurosciences raised $200 Million in a Funding Round round on October 21, 2025.
- Who invested in Minerva Neurosciences?
- Janus Henderson, Farallon and Vivo Capital are named as investors in this round.
- What does Minerva Neurosciences do?
- Dedicated to transforming the lives of patients with central nervous system diseases through innovative solutions.
- Where is Minerva Neurosciences based and how big is it?
- Minerva Neurosciences is based in Burlington, Massachusetts, United States. Fundz records about 8 employees.
- Who are the decision-makers at Minerva Neurosciences?
- Fundz holds 2 contacts at Minerva Neurosciences, including the Vice President, Controller. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Food and Beverage and Agriculture and Farming around the same time
Companies in the same sectors as Minerva Neurosciences that raised within 45 days of this round, from Fundz verified event records.
- Santhera Pharmaceuticals raised $21M (Funding Round) on September 23, 2025.
- Acasti raised $4M (Funding Round) on October 23, 2025.
- ISOThrive raised $8.1M on October 10, 2025.
- TORL BioTherapeutics raised $96M (Series C) on October 7, 2025.
- Axoltis Pharma raised $21M (Series A) on December 2, 2025.
- Azora Therapeutics, Inc. (DE) raised $4.3M on November 28, 2025.
Who to call at Minerva Neurosciences, and when
A new round usually means Minerva Neurosciences is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Minerva Neurosciences raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Minerva Neurosciences, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Minerva Neurosciences. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Minerva Neurosciences raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Minerva Neurosciences raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.